#United States #Laguna Hills #CPT Codes #UVB Therapy #LASEROPTEK

LASEROPTEK's Welcome to 2027 CPT Code Updates

Introduction
On November 9, 2026, LASEROPTEK America Corp. celebrated the American Medical Association’s (AMA) announced revisions to the 2027 Current Procedural Terminology (CPT®) code set. These changes particularly impact the group of codes ranging from 96920 to 96922 that are utilized to report targeted UVB laser therapies.

Significance of the Updates
Effective as of January 1, 2027, the revised descriptor for the aforementioned CPT code family states: "Laser treatment, 308-312 nanometer wavelengths, for inflammatory or autoimmune skin diseases (e.g., psoriasis)." This update streamlines the language used around laser technology and clarifies that the codes are technology-neutral. Such a designation ensures that the codings are applicable across various laser platforms that effectively deliver UVB light in the specified wavelength range. By removing ambiguity, the updated coding expands the treatment indications beyond just psoriasis, thereby facilitating a greater selection of technologies tailored to meet patient needs and clinical objectives.

Enhancing Clarity Across Technologies
With advancements in photonics engineering, the technological options for UVB phototherapy have significantly expanded. Among these advancements is solid-state laser technology, which has redefined the landscape of targeted UVB phototherapy. This update allows physicians to opt for various laser architectures, thereby allowing flexibility in selecting treatment systems suited for evolving clinical requirements. The shift to inclusive coding helps physicians assess different systems based not only on clinical utility but also on economic efficiency and practice demands.

Description of PALLAS Laser Systems
The LASEROPTEK portfolio includes the PALLAS and PALLAS Premium systems, which have both received U.S. FDA clearance for treating various inflammatory and autoimmune skin conditions. These are clinically versatile solid-state UVB laser systems that operate well within the newly defined wavelength range of 308 to 312 nanometers. The selection of the output wavelength is made by the physician during the ordering process, ensuring customization according to clinical needs.

Both systems can be acquired either through direct purchase or through a fixed-term rental arrangement, thereby allowing dermatology practices to manage their equipment expenses more predictably. The availability of two models under the PALLAS banner means physicians can make a choice that best suits their treatment volume and operational requirements.

A Legacy of Innovation
LASEROPTEK boasts over 26 years of expertise in developing and commercializing cutting-edge medical laser technologies tailored for dermatological applications. The company has successfully built a global presence with its PALLAS platform being used extensively across Asia, the Middle East, and the United States. Their vast clinical experience spans a thorough understanding of numerous inflammatory and autoimmune skin diseases, providing a robust framework for supporting physicians in the U.S. through educational initiatives, treatment protocol development, and practice integration.

The Mission Forward
Christopher Dalton, Vice President of LASEROPTEK America, articulated the company's commitment to improving patient care by leveraging medical innovation to enhance accessibility and effectiveness of treatments. They aim to provide physicians with advanced technologies that can cater to a wider range of patient needs.

Closing Thoughts
As LASEROPTEK increases its commercial presence in the U.S., they emphasize the importance of empowering dermatologists to make informed choices regarding targeted UVB laser technology. The company is dedicated to expanding not only the choices available to physicians but also patient access to these innovative therapies. Overall, the new clarify in coding standards laid out by the AMA will support both physicians and patients as they navigate the evolving landscape of dermatological treatment options.

For further information about LASEROPTEK and its range of products, visit www.laseroptek.com and www.pallaslaser.com.
Note: CPT® is a registered trademark of the American Medical Association. The AMA does not endorse any specific devices, and coding responsibility remains with physicians.